首页> 美国卫生研究院文献>Cancers >Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function
【2h】

Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function

机译:具有双成像和双靶功能的透明质酸酶响应介孔二氧化硅纳米粒子。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanoparticle-based drug delivery systems are among the most popular research topics in recent years. Compared with traditional drug carriers, mesoporous silica nanoparticles (MSN) offer modifiable surfaces, adjustable pore sizes and good biocompatibility. Nanoparticle-based drug delivery systems have become a research direction for many scientists. With the active target factionalized, scientists could deliver drug carriers into cancer cells successfully. However, drugs in cancer cells could elicit drug resistance and induce cell exocytosis. Thus, the drug cannot be delivered to its pharmacological location, such as the nucleus. Therefore, binding the cell membrane and the nuclear target on the nanomaterial so that the anticancer drug can be delivered to its pharmacological action site is our goal. In this study, MSN-EuGd was synthesized by doping Eu3+ and Gd3+ during the synthesis of MSN. The surface of the material was then connected to the TAT peptide as the nucleus target for targeting the cancer nucleus and then loaded with the anticancer drug camptothecin (CPT). Then, the surface of MSN-EuGd was bonded to the hyaluronic acid as an active target and gatekeeper. With this system, it is possible and desirable to achieve dual imaging and dual targeting, as well as to deliver drugs to the cell nucleus under a hyaluronidase-controlled release. The experimental approach is divided into three parts. First, we conferred the material with fluorescent and magnetic dual-imaging property by doping Eu3+ and Gd3+ into the MSN. Second, modification of the cell membrane target molecule and the nucleus target molecule occurred on the surface of the nanoparticle, making the nanoparticle a target drug carrier. Third, the loading of drug molecules into the carrier gave the entire carrier a specific target profile and enabled the ability to treat cancer. In this study, we investigated the basic properties of the drug carrier, including physical properties, chemical properties, and in vitro tests. The result showed that we have successfully designed a drug delivery system that recognizes normal cells and cancer cells and has good anticancer effects.
机译:基于纳米颗粒的药物递送系统是近年来最受欢迎的研究主题之一。与传统的药物载体相比,介孔二氧化硅纳米粒子(MSN)具有可修饰的表面,可调节的孔径和良好的生物相容性。基于纳米颗粒的药物递送系统已成为许多科学家的研究方向。通过分配主动目标,科学家可以成功地将药物载体传递到癌细胞中。但是,癌细胞中的药物可能引起耐药性并诱导细胞胞吐作用。因此,药物不能被递送到其药理位置,例如细胞核。因此,将细胞膜和核靶标结合在纳米材料上,以便可以将抗癌药物传递到其药理作用部位是我们的目标。在这项研究中,MSN-EuGd是通过在合成MSN时掺杂Eu 3 + 和Gd 3 + 来合成的。然后将材料表面连接到TAT肽作为靶向癌核的细胞核靶标,然后装载抗癌药物喜树碱(CPT)。然后,将MSN-EuGd的表面结合到透明质酸上作为活性靶和守门员。使用该系统,有可能并且希望实现双重成像和双重靶向,以及在透明质酸酶控制释放下将药物递送至细胞核。实验方法分为三个部分。首先,通过将Eu 3 + 和Gd 3 + 掺杂到MSN中,赋予材料具有荧光和磁双成像特性。第二,细胞膜靶分子和核靶分子的修饰发生在纳米颗粒的表面上,从而使纳米颗粒成为靶药物载体。第三,将药物分子装载到载体中使整个载体具有特定的靶标特征,并具有治疗癌症的能力。在这项研究中,我们研究了药物载体的基本特性,包括物理特性,化学特性和体外测试。结果表明,我们已经成功设计了一种识别正常细胞和癌细胞并具有良好抗癌作用的药物递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号